Clinical trials: Moderate Plaque Psoriasis
Psoriasis
Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with…
- Trial name
- REFINE (NCT01313221)
- Testing
- etanercept, Topical agents
- Where
- 24 sites in Canada
- Volunteers
- 310 people
- Sponsor
- Amgen
Chronic Plaque-type Psoriasis
A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis
This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate efficacy and safety of AUR101 (RORgamma inhibitor) in patients with moderate-to-severe psoriasis.
- Trial name
- INDUS-2 (NCT04207801)
- Testing
- AUR101
- Where
- 9 sites in India
- Volunteers
- 90 people
- Sponsor
- Aurigene Discovery Technologies Limited
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03364309
- Testing
- Ixekizumab
- Where
- 17 sites in China
- Volunteers
- 438 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of initial single and multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00320216
- Testing
- Ustekinumab
- Volunteers
- 320 people
- Sponsor
- Centocor, Inc.
Psoriasis
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
This is a Phase 2, multicenter, open-label study in subjects with moderate to severe plaque psoriasis aged 6 to 17 years, inclusive, intended to assess the safety, tolerability, and PK of apremilast with 2 weeks of oral…
- Trial name
- NCT02576678
- Testing
- Apremilast
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 42 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis, Psoriasis
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
- Trial name
- NCT02581345
- Testing
- M923, Humira
- Where
- 90 sites in United States, Bulgaria and 7 more
- Volunteers
- 572 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Psoriasis, Plaque Type Psoriasis
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study was to compare the efficacy, safety and immunogenicity of MSB11022 and Humira® in adult subjects with moderate to severe chronic plaque type psoriasis.
- Conditions
- Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis
- Trial name
- AURIEL-PsO (NCT02660580)
- Testing
- MSB11022, Humira®
- Where
- 76 sites in United States, Bulgaria and 10 more
- Volunteers
- 443 people
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Psoriasis
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
The study will investigate the efficacy and safety compared to placebo and the safety compared to ustekinumab of brodalumab in adolescents with moderate to severe plaque psoriasis.
- Trial name
- EMBRACE 1 (NCT04305327)
- Testing
- Brodalumab, Ustekinumab
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 12 people
- Sponsor
- LEO Pharma
Psoriasis
Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
W11-050 is a Mexican open label multicenter study that has been designed to further assess the safety and efficacy of adalimumab in the treatment of patients with active plaque psoriasis who have failed prior conventional…
- Trial name
- NCT01265823
- Testing
- Adalimumab
- Where
- 8 sites in Mexico
- Volunteers
- 150 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE RADIANT (NCT03536884)
- Testing
- Bimekizumab, Secukinumab
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 743 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00307437
- Testing
- Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
- Where
- 62 sites in United States, Austria and 5 more
- Volunteers
- 1,230 people
- Sponsor
- Centocor Research & Development, Inc.
Moderate Plaque Psoriasis
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate plaque psoriasis and special site involvement.
- Trial name
- SPECTREM (NCT06039189)
- Testing
- Guselkumab
- Where
- 64 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
CP-690-550 Ointment For Chronic Plaque Psoriasis
The study is being conducted to see whether CP-690,550 ointment has potential as a safe and effective treatment for adult patients with mild to moderate chronic plaque psoriasis.
- Trial name
- NCT01246583
- Testing
- CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- Pfizer
Moderate to Severe Plaque Psoriasis
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses
- Trial name
- AMAGINE-2 (NCT01708603)
- Testing
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab
- Where
- 153 sites in United States, Australia and 9 more
- Volunteers
- 1,831 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet
The purpose of this research study is to see how well (compared to placebo) Enbrel® (etanercept) 50 mg twice a week for 12 weeks affects plaque psoriasis of the hands and/or feet (palmoplantar psoriasis).
- Trial name
- NCT00585650
- Testing
- Etanercept
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of California, Irvine
Chronic Scalp Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis
This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
- Trial name
- SCALP (NCT02267135)
- Testing
- Secukinumab 300 mg
- Where
- 17 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis.
- Trial name
- NCT01745133
- Testing
- vehicle foam, calcipotriene, calcipotriene + clobetasol propionate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Leon Kircik, M.D.
Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar…
- Trial name
- NCT00601107
- Testing
- Doxercalciferol
- Where
- 19 sites in United States
- Volunteers
- 111 people
- Sponsor
- Genzyme, a Sanofi Company
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis
This is a 12 week bilateral study, consisting of 6 weeks of treatment and 6 weeks of follow-up. The purpose of the study is to compare the safety and effectiveness of combining and then following a high potency topical…
- Trial name
- NCT00769184
- Testing
- Corticosteroid, LCD
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NeoStrata Company, Inc.